John is a rheumatologist and immunologist with over 25 years of experience in academic medicine and the biotechnology industry. His research career has focused on developing novel therapies for patients with inflammatory and fibrotic diseases. He is an Independent Director of Sanofi S.A., a director of Neutrolis, Inc, and serves on the board of CARRA, the Childhood Arthritis and Rheumatology Research Alliance, and the Steering Committee of the NIH Immune Tolerance Network. Prior to joining Seismic John was Chief Medical Officer of Pandion Therapeutics, which was acquired by Merck in 2021 for $1.85 billion. He previously was Senior Vice President and Inflammation Therapeutic Area Head at Gilead Sciences. John led Gilead’s entry into inflammation and immunology and oversaw the clinical development of over a dozen new drug programs including Jyselica, which is approved in Europe and Japan for rheumatoid arthritis and/or ulcerative colitis. Before moving to industry, John was a tenured Associate Professor of Medicine at Duke University and Associate Professor at the Duke-National University of Singapore Graduate Medical School. An undergraduate from Bucknell University, John received his medical and scientific education at Drexel University, and residency and fellowship training at Duke. He has authored over 100 scientific publications.